Barnes & Noble (BKS) 23.10 $BKS Barnes & Noble Is More

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Barnes & Noble (BKS) 23.10 $BKS

Barnes & Noble Is More Profitable Than It Looks on the Surface
Jim Mueller, The Motley Fool - Motley Fool - Thu Mar 19, 2:24PM CDT
This article is part of the Real-Money Stock Picks portfolio series . I've been running the Messed-Up Expectations portfolio since November 2010, a bit shy of 4.5 years now. Over that time, I've both trailed and beaten the S&P 500 ....
NFLX: 428.30 (+3.09), AMZN: 378.49 (+5.25), GME: 40.92 (+0.13), BKS: 23.10 (-0.07)

Barnes & Noble: Still An Attractive Turnaround + Spin-Off Story
Jeremy Raper - at Seeking Alpha - Tue Mar 17, 7:15AM CDT

BKS: 23.10 (-0.07), MSFT: 42.88 (+0.60)

Is It Time for This Big Box Store to Change Management?
Daniel B. Kline, The Motley Fool - Motley Fool - Tue Mar 17, 7:04AM CDT
Barnes & Noble CEO Michael Huseby has only served in his post since January 2014. By most accounts, he has done an okay job stabilizing the retail business, growing its college segment, and transitioning the book-seller into new segments like...
AMZN: 378.49 (+5.25), BKS: 23.10 (-0.07)

Via Licensing and Barnes & Noble Settle Patent License Dispute Over NOOK(R) Tablets
Business Wire - Tue Mar 17, 5:00AM CDT
Via Licensing Corporation and Barnes & Noble, Inc. have settled litigation concerning the use of Advanced Audio Coding (AAC) technology in Barnes & Noble's NOOK(R) line of products. In late 2010, Barnes & Noble licensed AAC patent rights from Via's AAC patent pool comprised of 11 leading AAC standard essential patent owners under the AAC Patent License Agreement. Via filed suit against Barnes & Noble in 2013 for breach of the AAC Patent License Agreement and declaratory judgment. In the settlement, Barnes & Noble acknowledged that Via reasonably exercised its discretion in classifying the NOOK Color, NOOK Tablet, NOOK HD, and NOOK HD+ tablets under the AAC Patent License Agreement as consumer products that are subject to the standard rates. Barnes & Noble also acknowledged that the terms of the AAC Patent License Agreement are reasonable. Barnes & Noble has also agreed to pay royalties owed under the AAC Patent License Agreement.
BKS: 23.10 (-0.07)

Inland Private Capital Corporation Announces Sale of Fox River Commons Shopping Center in Wisconsin
Business Wire - Mon Mar 16, 10:06AM CDT
Inland Private Capital Corporation ("IPCC" today announced the sale of the Fox River Commons Shopping Center, a 78,977-square-foot retail destination located in Grand Chute, Wisconsin, for a gross sale price of $12,200,000. IPCC, through its subsidiary which serves as asset manager, facilitated the sale of the property on behalf of one of its 1031 investment programs.
BKS: 23.10 (-0.07)

NOOK(R) Announces the #NOOKReadingStyle Sweepstakes
Business Wire - Mon Mar 16, 7:30AM CDT
--Prizes Include a $500 Gilt E-Gift Card, a Samsung Galaxy Tab(R) 4 NOOK(R) and 100 $25 Barnes & Noble Gift Cards
BKS: 23.10 (-0.07)

Don't Judge Barnes & Noble By Its Cover
Daniel Jones - at Seeking Alpha - Sat Mar 14, 1:48AM CDT

BKS: 23.10 (-0.07)

Barnes & Noble Just Can't Compete With Kindle
Daniel James - at Seeking Alpha - Fri Mar 13, 10:14AM CDT

BKS: 23.10 (-0.07)

Insider Trading Alert - PF, BKS And HNSN Traded By Insiders
at The Street - Thu Mar 12, 12:35PM CDT
Stocks with insider trader activity include PF, BKS and HNSN
HNSN: 0.70 (unch), PF: 39.86 (-0.35), BKS: 23.10 (-0.07)

Barnes & Noble regains traction after earnings slide
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 12:07PM CDT

BKS: 23.10 (-0.07)

Stock Market News for March 11, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 9:10AM CDT
Benchmarks suffered huge losses on Tuesday as rate hike fears strengthened the U.S. dollar to a multi-year high against major currencies including the euro
URBN: 47.01 (+0.31), JPM: 61.75 (+0.55), C: 52.98 (+0.60), EOG: 90.68 (+1.15), XOM: 84.54 (+0.13), BAC: 15.84 (+0.23), WFC: 56.01 (+0.50), BKS: 23.10 (-0.07), MRO: 26.18 (+0.49), CVX: 107.03 (+2.28)

Barnes & Noble Slumps: BKS Falls 10.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 7:38AM CDT
Shares of Barnes & Noble (BKS) fell over 10% on the day. This continues the most recent downtrend for BKS, as the stock is down nearly 14% since Feb 26. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
BBW: 20.21 (-0.90), BKS: 23.10 (-0.07)

Barnes & Noble posts net earnings of USD72m in Q3 fiscal 2015
M2 - Wed Mar 11, 5:51AM CDT
Barnes & Noble Inc (NYSE:BKS), a bookseller and retailer of content, digital media and educational products, on Tuesday reported consolidated net earnings of USD72m, or USD0.93 per share, for the third quarter of fiscal 2015, ended 31 January 2015.
BKS: 23.10 (-0.07)

Nook sinks on Amazon weight
at Investor's Business Daily - Tue Mar 10, 5:50PM CDT
After changing its mind recently and deciding to keep its Nook business after all, Barnes & Noble (BKS) said that sales of the e-reader sank 51% in its fiscal Q3, leading to a huge earnings miss for the company as Amazon's (AMZN) Kindle continued to...
AMZN: 378.49 (+5.25), BKS: 23.10 (-0.07)

The Single Worst Practice of Cable Providers
Anders Bylund, The Motley Fool - Motley Fool - Tue Mar 10, 4:15PM CDT
The cable industry is overflowing with business problems. Potty-mouthed Comcast service reps stand shoulder to shoulder with near-impossible cancellation policies . The industry is trying to consolidate for all the wrong reasons . And from a...
T: 33.23 (+0.03), AMZN: 378.49 (+5.25), CHTR: 189.01 (+0.83), TWC: 157.87 (+2.26), BKS: 23.10 (-0.07), VZ: 49.56 (+0.26), AAPL: 125.90 (-1.60), CMCSA: 59.45 (+0.71)

Stocks Settle at One-Month Low as Fed Rate Fears Spark Selloff
at The Street - Tue Mar 10, 3:05PM CDT
Wall Street was bruised and battered on Tuesday as uncertainty over a Federal Reserve rate hike timeline played havoc with stocks.
URBN: 47.01 (+0.31), CS: 26.47 (+1.17), LL: 28.51 (-0.84), BKS: 23.10 (-0.07), TWTR: 48.44 (+0.51)

Barnes & Noble (BKS) Michael P. Huseby on Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 10, 2:31PM CDT

BKS: 23.10 (-0.07)

S&P 500 and Dow Erase Gains for 2015 as Dollar Pushes Higher
at The Street - Tue Mar 10, 2:30PM CDT
Stocks fall more than 1% on Tuesday as uncertainty over a Federal Reserve rate hike timeline pushes the dollar to 12-year highs.
URBN: 47.01 (+0.31), CS: 26.47 (+1.17), PNC: 95.97 (+1.10), LL: 28.51 (-0.84), BKS: 23.10 (-0.07), TWTR: 48.44 (+0.51)

Why Barnes & Noble, Inc.'s Shares Flopped Today
Alex Planes, The Motley Fool - Motley Fool - Tue Mar 10, 2:17PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Barnes & Noble had lost 9% of their...
BKS: 23.10 (-0.07)

Barnes & Noble (BKS) Stock Declines Today Following Earnings Miss
at The Street - Tue Mar 10, 12:51PM CDT
Barnes & Noble (BKS) shares are falling after the company missed analysts' earnings estimates for the quarter.
BKS: 23.10 (-0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading